Aller au contenu principal
Profil bibliographique

Teresa S. Hyun

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

54Publications signalées
1263Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Multiple Myeloma Research and TreatmentsGenetic Neurodegenerative DiseasesChronic Myeloid Leukemia TreatmentsUbiquitin and proteasome pathwaysChronic Lymphocytic Leukemia Research

Les publications récentes

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres

Supplemental Table. Grade 3-5 adverse events possibly, probably or definitely attributed to imatinib or rituximab Supplemental Figure 1. Vienna Skin Score (VSS) (1) Supplemental Figure 2. Photograph Range of Motion Scale - Modified from (2) Supplemental Figure 3. Total numbers of B …

0 citations
Accès ouvert 2023 other OpenAlex

Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres

Abstract Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of imatinib (200 mg daily) or rituximab …

0 citations
Accès ouvert 2023 other OpenAlex

Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres

Abstract Purpose: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. Experimental design: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of imatinib (200 mg daily) or rituximab …

0 citations
Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Data from A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai et autres

Supplemental Table. Grade 3-5 adverse events possibly, probably or definitely attributed to imatinib or rituximab Supplemental Figure 1. Vienna Skin Score (VSS) (1) Supplemental Figure 2. Photograph Range of Motion Scale - Modified from (2) Supplemental Figure 3. Total numbers of B …

0 citations
Accès ouvert 2023 other OpenAlex

Data from Aberrant Huntingtin Interacting Protein 1 in Lymphoid Malignancies

Sarah V. Bradley, Mitchell Robert Smith, Teresa S. Hyun, Peter C. Lucas et autres

Abstract Huntingtin interacting protein 1 (HIP1) is an inositol lipid, clathrin, and actin binding protein that is overexpressed in a variety of epithelial malignancies. Here, we report for the first time that HIP1 is elevated in non–Hodgkin's and Hodgkin's lymphomas and that …

us (code pays fourni par la source)

0 citations
Accès ouvert 2023 other OpenAlex

Data from Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor

Sarah V. Bradley, Eric C. Holland, Grace Y. Liu, Dafydd G. Thomas et autres

Abstract Huntingtin interacting protein 1 (HIP1) is a multidomain oncoprotein whose expression correlates with increased epidermal growth factor receptor (EGFR) levels in certain tumors. For example, HIP1-transformed fibroblasts and HIP1-positive breast cancers have elevated EGFR protein levels. The combined association of HIP1 …

us (code pays fourni par la source)

0 citations
Accès ouvert 2023 other OpenAlex

Data from Huntingtin Interacting Protein 1 Is a Novel Brain Tumor Marker that Associates with Epidermal Growth Factor Receptor

Sarah V. Bradley, Eric C. Holland, Grace Y. Liu, Dafydd G. Thomas et autres

Abstract Huntingtin interacting protein 1 (HIP1) is a multidomain oncoprotein whose expression correlates with increased epidermal growth factor receptor (EGFR) levels in certain tumors. For example, HIP1-transformed fibroblasts and HIP1-positive breast cancers have elevated EGFR protein levels. The combined association of HIP1 …

us (code pays fourni par la source)

0 citations

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.